• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·India·Healthcare·LYKALABS.NS
Share

Lyka Labs Limited Stocks

₹ 62.53Last Updated 24.07.2026

Issuer Rating

3/7
Performance

Average

Risk

High

Recommendation

Sell

Market Cap

₹ 26.01M

₹ 62.53
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Established in 1976 and headquartered in Mumbai, India, Lyka Labs Limited is a pharmaceutical firm specializing in the development, manufacturing, and marketing of a wide array of pharmaceutical formulations and active pharmaceutical ingredients (APIs). The company's extensive product portfolio addresses numerous therapeutic areas, including intensive care, gastroenterology, anti-infectives, anti-fungals, surgery, urology, wound care, anesthesia, and various dermatological and cosmeceutical applications like topical steroids, anti-acne, anti-aging, and hair care. These products are available in diverse forms, such as injections, creams, ointments, gels, and lotions. Beyond its own offerings, Lyka Labs also provides contract manufacturing services to other major pharmaceutical companies and offers comprehensive medical and technical support. This support includes manufacturing expertise, facility assistance, and crucial technical data such as molecule stability testing, impurity profiling, and bioequivalence (BA/BE) clinical study data. The company's market reach extends globally, with exports to various countries including Bangladesh, Cambodia, Congo, Costa Rica, Peru, Romania, Russia, Sri Lanka, Sudan, Ukraine, Venezuela, and Vietnam.

Company Valuation

Fairly valued
4/7

Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers. In particular, the stock is trading at neutral levels on P/FCF

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

26.07.2026 21:33

Revolut Valued at $115 Billion and a Record-Breaking Deal in Asia: Key Takeaways on IPOs as of July 26

26.07.2026 15:01

AI Tools to Combat Cognitive Biases: How Investors Can Use Them

25.07.2026 16:01

Small caps last week: New Nasdaq rules, AI hurting Tripadvisor, Archer's rotorcraft

25.07.2026 13:50

Chevron Discussed with the U.S. How to Protect Its Interests in Kazakhstan from the Effects of the War — WSJ

25.07.2026 13:01

The "Three Seas" Risk Zone, Tesla Hit by Expenses, and "Odyssey" — the Driving Force Behind Movie Theaters

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026